News

February 25, 2019

More Intense Chemotherapy May Lower Risk of Breast Cancer Recurrence and Death, Study Says

News

Reducing the interval between chemotherapy treatment cycles or administering chemotherapy medications sequentially at higher doses, rather than simultaneously at lower doses, increases treatment efficacy and decreases the risk of breast ... Read more

February 22, 2019

Plerixafor Improves Immunotherapy Response in Mouse Model of Breast Cancer

News

Plerixafor — approved for the treatment of lymphoma and multiple myeloma — decreases tumor fibrosis and improves immunotherapy response in a mouse model of metastatic breast cancer, a study finds. The ... Read more

February 18, 2019

Young Survival Coalition Hosts Summit for BC Survivors, Supporters

News

More than 600 young breast cancer survivors will gather in Austin, Texas, for the 4th Annual Young Survival Coalition (YSC) Summit. For such survivors, it’s the only national conference. In ... Read more

February 15, 2019February 18, 2019

Experimental Compound Could Broaden HER2-targeted Approach to BC

News

By targeting small regulatory molecules called microRNAs (miRNAs), researchers were able to reprogram breast cancer cells and render them sensitive to HER2-targeting medicines, such as Herceptin (trastuzumab) and Kadcyla (ado-trastuzumab emtansine), a study ... Read more

February 13, 2019

Changes in Gene Expression May Hint at Relapse Risk in ER-positive Patients on Hormone Therapy, Study Finds

News

Specific changes in gene expression might help to predict the risk of relapse in estrogen receptor (ER)-positive breast cancer patients under hormone therapy, a study reports. The study, “Molecular changes ... Read more

February 11, 2019

Margetuximab Helps to Delay Disease Progression in Advanced, HER2-positive Breast Cancers, Phase 3 Trial Shows

News

A combination of MacroGenics‘ HER2 antibody margetuximab and standard chemotherapy is superior to Herceptin (trastuzumab) plus chemotherapy at extending the time to disease progression among advanced and pre-treated breast cancer patients whose tumors ... Read more

February 8, 2019

FDA to Review Kadcyla for Certain HER2-positive Early-stage Breast Cancer Patients

News

The U.S. Food and Drug Administration is reviewing Kadcyla (trastuzumab emtansine) as a post-surgery treatment for early-stage breast cancer patients whose tumors produce the HER2 factor, Roche announced. The supplemental biologics license application ... Read more

February 6, 2019

Knight Therapeutics Acquires Exclusive Marketing Rights to Nerlynx in Canada

News

Breast cancer treatment Nerlynx (neratinib) will be exclusively commercialized in Canada by Knight Therapeutics, under an agreement with the therapy’s developer, Puma Biotechnology. Nerlynx is currently being reviewed by Health Canada as a ... Read more

February 4, 2019

Breast Cancers Diagnosed Within 10 Years of Pregnancy Have Higher Risk of Metastasis, Study Shows

News

Women diagnosed with breast cancer up to 10 years after giving birth have a higher risk of metastasis than childless women of the same age, a study says. The study, ... Read more

February 1, 2019

Blocking Interaction Between Blood Vessels, Cancer Cells Could Prevent Disease’s Spread, Study Says

News

Blocking the interaction between cancer cells and their microenvironment could be a viable strategy to eliminate cancer cells that stray from the primary tumor, thereby preventing cancer’s spread, according to ... Read more